Company profile

AC Immune SA

AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s Disease drug development. We are developing innovative therapeutics with “best in class” potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules.

Source: startup.ch

More news about AC Immune SA

29.12.2023 14:00

AC Immune raises USD50 million

Financing

06.12.2023 17:00

Leadership changes with some promotions

Background

02.09.2021 16:35

Fünf Unternehmerinnen und Unternehmer am SEF 2021 ausgezeichnet

Award

28.07.2021 13:46

AC Immune acquires Parkinson’s disease vaccine candidate and equity investment

Financing

03.08.2020 09:12

AC Immune’s therapeutic and diagnostic programs for Parkinson’s achieve milestones

Success

19.06.2019 09:29

“With setbacks, the most important thing is to show strength”

Background

30.01.2019 16:00

Serious setback for AC Immune

Setback

14.12.2018 08:28

AC Immune and Eli Lilly sign billion-dollar agreement

Success

02.11.2017 16:42

AC Immune to receive milestone payment from Genentech

Success

23.09.2016 09:43

AC Immune raises more than CHF 50 million in its IPO

Financing

14.09.2016 09:07

AC Immune goes public

Financing

07.07.2016 09:10

AC Immune to receive CHF14 million under collaboration agreement with Genentech

Success

Support

01.06.2016 12:42

AC Immune files for IPO

Financing

09.05.2016 09:30

AC Immune raises USD 43.5 million

Financing

05.04.2016 16:21

AC Immune’s publication on the treatment of Down Syndrome

Background

Success

08.01.2016 08:11

AC Immune brings treatment for Alzheimer’s disease into the Down syndrome population

Expansion

23.09.2015 09:16

Nestlé and AC Immune collaborate to identify Alzheimer’s patients at very early stage

Success

24.07.2015 15:01

Another milestone for AC Immune

Success

14.07.2015 12:44

Milestone for AC Immune from Genentech

Success

13.02.2015 09:18

AC Immune Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research

Support

12.01.2015 08:15

AC Immune Enters into License and Collaboration Agreement worth up to CHF 500 million

Success

09.01.2014 14:22

AC Immune raises CHF 20 million and initiates vaccine trial for Alzheimer’s disease

28.11.2013 09:25

AC Immune CEO Andrea Pfeifer awarded Prix BioAlps 2013

Award

21.09.2012 09:23

AC Immune Named One of Fierce 15 Leading Biotech Companies

Award

18.06.2012 09:30

AC Immune and Genentech enter into second collaboration

16.05.2012 10:17

AC Immune Therapy chosen for ground-breaking Alzheimer´s Disease Trial

Founded
2003

Kanton
VD

Homepage

Principal

Swiss Venture Capital Report

The new Swiss Venture Capital Report provides a review of the whole of 2023. In addition to investments, the report will once again include the results of a survey of Swiss investors, an overview of venture capital fundraising and a list of exits. You can download the Report in our asset section.